29.05.2013 Views

Presentazione di PowerPoint - Master in Pneumologia Interventistica

Presentazione di PowerPoint - Master in Pneumologia Interventistica

Presentazione di PowerPoint - Master in Pneumologia Interventistica

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

UNITA’ DI TERAPIA INTENSIVA PNEUMOLOGICA<br />

E FISIOPATOLOGIA TORACICA<br />

Direttore Dr. A. Corrado<br />

Ruolo della FBS <strong>in</strong> Unità <strong>di</strong> Terapia<br />

Intensiva Respiratoria<br />

Firenze, 07.05.2012<br />

Antonio Corrado<br />

Teresa Renda


Fiberoptic Bronchoscopy (FOB) <strong>in</strong> Intensive Care<br />

RICU<br />

ICU Disponibilità dello strumento<br />

nelle Terapie Intensive<br />

polivalenti: 87%<br />

Dati generali dal Rapporto GiViTi 2002<br />

a cura <strong>di</strong> Rossi C et al.<br />

Dall’analisi della letteratura si ev<strong>in</strong>ce che la FOB <strong>in</strong> ICU<br />

è condotta su pz sottoposti a ventilazione meccanica <strong>in</strong><br />

una percentuale dal 65-79%.


In<strong>di</strong>cations for bronchoscopy<br />

<strong>in</strong> the RICU/ICU<br />

Diagnostic<br />

Secretion/atelectasis<br />

management<br />

Hemoptysis<br />

Pulmonary <strong>in</strong>filtrates <strong>di</strong>agnosis<br />

Failed extubation<br />

Un<strong>di</strong>agnosed x-ray change<br />

Central airway obstruction<br />

Management of tracheostomy<br />

and evaluation of airways<br />

patency before decannulation<br />

Therapeutic<br />

Secretion/atelectasis<br />

management<br />

Hemoptysis<br />

Foreign body removal<br />

Difficult <strong>in</strong>tubation and<br />

tracheal tube position<strong>in</strong>g<br />

Percutaneous tracheostomy<br />

guidance


Fiberoptic Bronchoscopy (FOB) <strong>in</strong> the Airway<br />

management of the critically ill patients<br />

Intubated PTS<br />

Not <strong>in</strong>tubated PTS<br />

FOB performed <strong>in</strong> ICU <strong>in</strong> critically ill patients is relatively safe,<br />

but an appropriate risk–benefit analysis is always necessary.<br />

When bronchoscopy is performed on extubated patients, stability<br />

of oxygenation and ventilation must be assessed and the risk of<br />

respiratory failure from sedation, me<strong>di</strong>cations, or the procedure<br />

itself must be determ<strong>in</strong>e.<br />

The bronchoscopist must be skilled <strong>in</strong> <strong>in</strong>tubation either by <strong>di</strong>rect<br />

laryngoscopy or over a bronchoscope, <strong>in</strong> case of respiratory<br />

failure.


SAFETY OF FOB IN THE<br />

CRITICALLY ILL PATIENTS<br />

The severity of illness (respiratory failure, emodynamic<br />

compromise, or other critical organ system dysfunction)<br />

should not be considered a barrier to FOB and obta<strong>in</strong><strong>in</strong>g<br />

valuable data that could impact patient management.<br />

Diagnostic FOB with BAL is safe even <strong>in</strong> pats who meet<br />

cl<strong>in</strong>ical criteria for adult respiratory <strong>di</strong>stress syndrome<br />

(PaO2/FiO2 ≤ 200).<br />

Common RICU/ICU problems <strong>in</strong>clu<strong>di</strong>ng coagulopathy and<br />

platelet dysfunction (as well as therapeutic<br />

anticoagulation with warfar<strong>in</strong> or hepar<strong>in</strong>) are<br />

contra<strong>in</strong><strong>di</strong>cations to the use of transbronchial biopsy.<br />

A skilled team with specific expertice is required


CONTROINDICAZIONI ?<br />

Con<strong>di</strong>zioni ad elevato rischio<br />

• Aritme car<strong>di</strong>ache severe<br />

• Ang<strong>in</strong>a <strong>in</strong>stabile<br />

• Ischemia <strong>in</strong> atto<br />

• Infarto miocar<strong>di</strong>co recente (< 6 settimane)<br />

• Ipossiemia grave refrattaria<br />

• Grave <strong>di</strong>atesi emorragica<br />

• Broncospamo serrato <strong>in</strong> atto<br />

• Ipertensione endocranica<br />

CONTROINDICAZIONI<br />

Inesperienza dell’operatore<br />

Mo<strong>di</strong>fied by: BTS Guidel<strong>in</strong>es on <strong>di</strong>agnostic flexible bronchoscopy, Thorax 2001


Legate alla preme<strong>di</strong>cazione:<br />

o Depressione respiratoria<br />

o Ipotensione transitoria<br />

Legate all’anestesia:<br />

o Arresto respiratorio<br />

o Collasso car<strong>di</strong>ovascolare<br />

o Convulsioni<br />

Complicanze<br />

Legate alla broncoscopia:<br />

o Ipossiemia/ipercapnia<br />

o Bronco-Lar<strong>in</strong>gospasmo<br />

o Aritmie car<strong>di</strong>ache (↓ Pa02)<br />

o Ipotensione o crisi ipertensive<br />

o Reazione vagale<br />

o Barotrauma<br />

o Febbre (soprattutto nel BAL )<br />

o Epistassi, nausea ,vomito<br />

o Infettive/Polmoniti<br />

o Legate alle tecniche usate (pnx,<br />

pneumopnx, emorragie)<br />

Le complicanze maggiori occorrono <strong>in</strong> meno dell’ 1% dei casi e la<br />

mortalità legata alla procedura è rara (< 0.05%)<br />

Ernst A et al. Guidel<strong>in</strong>es from ACCP. Chest 2003; 123:1693-1717


RACCOMANDAZIONI durante FBS<br />

<strong>in</strong> pz non <strong>in</strong>tubato<br />

0 2-terapia (M. Venturi, occhiali nasali, SNF)<br />

Ventilazione assistita (NIV) e 0 2-terapia<br />

Monitorizzazione Sp0 2, PA, ECG<br />

Monitorizzazione transcutanea del C0 2<br />

Monitorizzazione PIC<br />

RACCOMANDAZIONI dopo FBS<br />

Eventuale antagonismo dei sedativi<br />

Somm<strong>in</strong>istrazione 0 2-terapia<br />

Proseguire NIV se necessario<br />

Monitorizzazione Sp0 2, PA, ECG<br />

Rx torace urgente (se si affettua biopsia, posizion. stent,…)<br />

Digiuno per almeno 2 h al term<strong>in</strong>e dell’esame<br />

Mo<strong>di</strong>fied by BTS Guidel<strong>in</strong>es on <strong>di</strong>agnostic flexible bronchoscopy, Thorax 2001


RACCOMANDAZIONI DURANTE VM<br />

Mettere boccaglio anti-morso se necessario<br />

Utilizzare un tubo IT con Ø non < a 8 mm con FBS <strong>di</strong> Ø <strong>di</strong> 5,7 mm<br />

Posizionare apposito mounth per evitare per<strong>di</strong>te aeree e lubrificare FBS<br />

Incrementare Fi0 2 (100%) 15’’ prima, durante FBS e dopo circa 1 h.<br />

Elim<strong>in</strong>are o ridurre del 50% la PEEP durante FBS<br />

Aumentare la Pi (se si utilizza PCV) e limite superiore <strong>di</strong> allarme a causa<br />

delle resistenze del tubo<br />

Sedare il paziente per:<br />

Prevenire contrasto con ventilatore<br />

Prevenire aumento PIC da tosse o agitazione<br />

Incrementare Vt del 30% se il paziente è ventilato <strong>in</strong> modalità volumetrica<br />

Monitorare EGA, PetC0 2, Sp0 2<br />

Fare brevi aspirazioni (circa 3”) per evitare riduzione del Vt<br />

Mo<strong>di</strong>fied by DYH Tai, Ann Acad of Me<strong>di</strong>c<strong>in</strong>e 1998; 27: 552-559


FOB IN THE INTUBATED PATIENT<br />

It is important to<br />

know the<br />

<strong>di</strong>fference between<br />

<strong>di</strong>ameters of FOB<br />

and ET, before<br />

bronchoscopy


L’<strong>in</strong>troduzione del FBS <strong>in</strong> un pz non IOT occupa il 10-15 % della<br />

sezione trasversa della trachea<br />

L’aumento delle resistenze all’<strong>in</strong>terno<br />

della trachea provocate dalla presenza<br />

del TO e del FBS determ<strong>in</strong>a un<br />

<strong>in</strong>completo svuotamento del polmone <strong>in</strong><br />

espirazione con rischio <strong>di</strong> barotrauma.<br />

E’ necessario pre<strong>di</strong>sporre tubi e FBS <strong>di</strong><br />

grandezza adeguata :<br />

un FBS con Ø esterno <strong>di</strong> 5,7 mm<br />

occupa:<br />

-40% <strong>di</strong> un ETT con ID <strong>di</strong> 9 mm<br />

-51% <strong>di</strong> un ETT con ID <strong>di</strong> 8 mm<br />

-66% <strong>di</strong> un ETT con ID <strong>di</strong> 7 mm<br />

FOB nel pz <strong>in</strong>tubato <strong>in</strong> IMV<br />

In pratica: è auspicabile usare tubi con ID <strong>di</strong> almeno 8 mm e FBS<br />

con Ø esterno al max <strong>di</strong> 5,7 mm


ST<br />

OP


FOB IN<br />

NOT INTUBATED<br />

PATIENT


FBS nel paziente fortemente ipossiemico<br />

Ruolo della NIV<br />

La grave ipossiemia rappresentava una<br />

contro<strong>in</strong><strong>di</strong>cazione relativa alla esecuzione<br />

dell’esame specie per alcune meto<strong>di</strong>che come il<br />

BAL.<br />

Diversi stu<strong>di</strong> hanno <strong>di</strong>mostrato una netta<br />

superiorità della NIV rispetto alla<br />

ossigenazione <strong>in</strong> maschera, <strong>in</strong> pazienti<br />

fortemente ipossiemici sottoposti a FBS, nel<br />

mantenimento <strong>di</strong> una buona saturazione.<br />

Antonelli M et al. Non<strong>in</strong>vasive positive-pressure ventilation via face mask dur<strong>in</strong>g<br />

bronchoscopy with BAL <strong>in</strong> high-risk hypoxemic patients. Chest (1996) 110:724-728<br />

Antonelli Met al. Non<strong>in</strong>vasive positive-pressure ventilation vs conventional oxygen<br />

supplementation <strong>in</strong> hypoxemic patients undergo<strong>in</strong>g <strong>di</strong>agnostic bronchoscopy. Chest (2002)<br />

121:1149-1154


Chest 1996;110:724-28<br />

Study population<br />

8 immunosuppressed patients<br />

(40±14 years old) with<br />

suspected Pneumonia<br />

Entrance criteria<br />

1) PaO2/FI02 ≤100;<br />

2) pH ≥ 7.35;<br />

3) improvement <strong>in</strong> SatO2 dur<strong>in</strong>g<br />

NPPV before <strong>in</strong>itiat<strong>in</strong>g FOB.


Methodology of NPPV and FOB<br />

Rout<strong>in</strong>e application of topical anesthesia to the nasopharynx.<br />

The FIO2 was kept at 0.7 while the pats adjusted to the system (at<br />

least 15 m<strong>in</strong>). A full face mask was connected to a ventilator.<br />

Ventilator sett<strong>in</strong>g: CPAP 4 cm H2O, PSV 17 cm H2O, FI02 100%.<br />

The mask was secured to the pat with head straps.<br />

NPPV: began 10 m<strong>in</strong> before start<strong>in</strong>g FOB and cont<strong>in</strong>ued for 90 m<strong>in</strong><br />

or more after the procedure was completed. The bronchoscope<br />

was passed through a T-adapter and advanced through the nose.<br />

BAL was obta<strong>in</strong>ed by sequential <strong>in</strong>stillation and aspiration of 5 to<br />

25 mL aliquots of sterile sal<strong>in</strong>e solution through a bronchoscope<br />

wedged <strong>in</strong> a ra<strong>di</strong>ographically <strong>in</strong>volved subsegment<br />

After bronchoscopy: the FI02 was decreased to 0.7.<br />

Oxygen saturation, heart rate, respiratory rate, and arterial blood<br />

gases were monitored dur<strong>in</strong>g the study.


Results<br />

NPPV significantly<br />

improved Pa02/FIo2 and<br />

O2 saturation<br />

No patient required<br />

endotracheal <strong>in</strong>tubation.<br />

A causative pathogen<br />

was identified by BAL <strong>in</strong><br />

all pats.


NPPV, before FOB<br />

FOB: through the vocal cords<br />

FOB: <strong>in</strong> the wedge position<br />

NPPV, after the withdrawal of FOB


Am J Respir Crit Care Med 2000;<br />

162:1063–1067


Study design


Dur<strong>in</strong>g the 48 h after FOB:<br />

2 ad<strong>di</strong>tional pats <strong>in</strong> the Oxygen group were <strong>in</strong>tubated at 24 h, and 2 <strong>in</strong> the<br />

CPAP group at 48 h.


12 hypoxemic non-ICU patients. Patients were admitted to the<br />

ICU solely for the purpose of bronchoscopy.


Methodology<br />

20 m<strong>in</strong>utes before bronchoscopy : pats were connected to NPPV<br />

to allow acclimatization. Topical anesthesia of the mouth and pharynx<br />

was achieved with xyloca<strong>in</strong>e spray (10%).<br />

Ventilator sett<strong>in</strong>g: PEEP 6 cm H2O, PSV 10 cm H2O, FI02 100%.<br />

The bronchoscope was <strong>in</strong>troduced via the plastic cyl<strong>in</strong>der <strong>in</strong> the face<br />

mask.<br />

After bronchoscopy: PS and FiO2 were tapered while ma<strong>in</strong>ta<strong>in</strong><strong>in</strong>g<br />

SatO2>92%. When FiO2 was decreased to 0.4, while pats<br />

ma<strong>in</strong>ta<strong>in</strong>ed SatO2>92% without respiratory <strong>di</strong>stress, NPPV was<br />

<strong>di</strong>scont<strong>in</strong>ued. Oxygen was then supplemented through a<br />

nonrebreath<strong>in</strong>g mask.<br />

Patients rema<strong>in</strong>ed <strong>in</strong> the ICU for 12–24 h with<br />

cont<strong>in</strong>uously monitor<strong>in</strong>g of SpO2 and heart rhythm.


… several precautions should be considered.<br />

First, <strong>in</strong> these high-risk patients bronchoscopy should be<br />

performed by an experienced physician and <strong>in</strong> the<br />

presence of staff tra<strong>in</strong>ed <strong>in</strong> emergency endotracheal<br />

<strong>in</strong>tubation.<br />

Second, occasionally prolonged non-<strong>in</strong>vasive ventilation is<br />

needed after bronchoscopy <strong>in</strong> these patients.<br />

Because of <strong>in</strong>duction of shunt and possible <strong>in</strong>flammatory<br />

response due to lavage solution, approximately 24 h<br />

monitor<strong>in</strong>g is recommended .


BAL IN<br />

NOT INTUBATED<br />

PATIENT


Caso cl<strong>in</strong>ico: SL<br />

anni 74, sesso F, Ipertesa,<br />

Insufficienza renale cronica lieve,<br />

DM II, da 6 mesi terapia con<br />

Metotrexato e plaquenil per<br />

rizoartrosi<br />

Episo<strong>di</strong>o simil-<strong>in</strong>fluenzale<br />

(30/03) curato a domicilio con<br />

antibiotici<br />

10.04.10<br />

Dispnea <strong>in</strong>gravescente<br />

Ingresso al DEA<br />

EGA <strong>in</strong> aria ambiente:<br />

PaO2 34, PaCO2 29, pH 7.47<br />

30-03-2010<br />

10-04-2010


AngioTc e Tc Torace: esclusa<br />

TEP… presenza <strong>di</strong> addensamenti<br />

parenchimali multipli con aree<br />

consolidative a vetro smerigliato ed<br />

<strong>in</strong>teressamento <strong>in</strong>terstiziale<br />

Trasferita prima<br />

<strong>in</strong> Mal Infettive e poi <strong>in</strong><br />

RICU<br />

14-04. EGA <strong>in</strong> O2 con Reservoir (15 L/m<strong>in</strong>):PaO2 77, PaCO2 31, pH 7.46<br />

Eseguiva cicli <strong>di</strong> NIV (prima CPAP poi Bilevel) con buona correzione dello stato <strong>di</strong><br />

ossigenazione durante ventilazione e peggioramento <strong>in</strong> assenza <strong>di</strong> supporto ventilatorio.<br />

19-04. Viene eseguito BAL a scopo <strong>di</strong>agnostico (obbligatoriamente <strong>in</strong> NIV).<br />

EGA durante NIV (NPPV:IPAP 18-EPAP 5)+ FiO2 100%:PaO2 78, PaCO2 42, pH 7.40<br />

(pre-FBS)<br />

EGA durante NIV (NPPV:IPAP 18-EPAP 5)+ FiO2 100%:PaO2 95, PaCO2 50, pH 7.32<br />

(f<strong>in</strong>e-BAL)


Dopo FOB è stato necessario proseguire il<br />

trattamento con NIV (casco) <strong>in</strong> modo cont<strong>in</strong>uativo<br />

Intolleranza al trattamento con NIV <strong>in</strong> maschera facciale e<br />

casco. Necessità <strong>di</strong> alti flussi <strong>di</strong> ossigeno <strong>in</strong> respiro spontaneo<br />

(reservoir con O2 30 L/m<strong>in</strong>; PaO2 48 mmHg)<br />

21/04/2009<br />

IOT


Secretion/atelectasis<br />

management


FBS<br />

A “ suction catheter with an eye”<br />

DM Geddes. Intens Care Med 1980. 6, 145-146


Critical Care 2008, 12:209 (doi:10.1186/cc6830)


•Insorgenza rapida<br />

•Peggioramento EGA<br />

•Co<strong>in</strong>volgimento <strong>di</strong><br />

segmenti ampi (assenza<br />

bcg-aereo)<br />

•Tosse <strong>in</strong>efficace<br />

•Sospetto <strong>di</strong> corpi<br />

estranei


Non è stata ancora <strong>di</strong>mostrata la superiorità della FBS rispetto alle<br />

tecniche <strong>di</strong> fisioterapia precoce.


Caso cl<strong>in</strong>ico BM<br />

87 aa<br />

BPCO, CPC<br />

Fibrotorace sx post-TBC<br />

Ipertensione Arteriosa<br />

Epatopatia Alcolica<br />

Rx torace<br />

EGA<br />

Ingresso al DEA<br />

24-01-2009<br />

GCS: 8<br />

paO2 paCO2 pH<br />

33 96 7.11<br />

Fibrotorace sx estesamente<br />

calcificato….<br />

Alla base <strong>di</strong> dx, <strong>in</strong><br />

paracar<strong>di</strong>aca, addensamento<br />

parenchimale con<br />

broncogramma aereo.


BM: DEGENZA IN UTIP<br />

Nei giorni<br />

successivi<br />

Cicli <strong>di</strong> NPPV-NPV<br />

Rx 3O-01-09<br />

EGA FiO2 40% al term<strong>in</strong>e NPV<br />

paO2 paCO2 pH<br />

90 71 7.44<br />

Tappi <strong>di</strong> muco<br />

SCAMBI<br />

RESPIRATORI<br />

scarsa autonomia<br />

ventilatoria<br />

Post-FBS:31-01-09<br />

EGA FiO2 40% paO2 paCO2 pH<br />

74 58 7.44<br />

Nei gg successivi sospesa VM


Caso cl<strong>in</strong>ico LM<br />

27 aa<br />

Distrofia Muscolare Duchenne<br />

Car<strong>di</strong>opatia Ipoc<strong>in</strong>etica Dilatativa<br />

Portatore tracheostomia (IMV) e<br />

PEG<br />

Trasferito da<br />

altro reparto<br />

08-04-2010<br />

08-04. EGA <strong>in</strong> O2 (2 L/m<strong>in</strong>) ed IMV (PS 12-PEEP 5): PaO2 90, PaCO2 55, pH 7.40<br />

11-04. EGA <strong>in</strong> O2 (2 L/m<strong>in</strong>) ed IMV (PS 12-PEEP 5): PaO2 64, Pa CO2 54, pH 7.41<br />

13/04. Si esegue FBS:<br />

presenza <strong>di</strong> tappi <strong>di</strong> muco <strong>in</strong><br />

tutto l’emisistema bronchiale<br />

sx


Nei giorni successivi<br />

15/04 21/04<br />

15-04. EGA <strong>in</strong> O2 (2 L/m<strong>in</strong>) ed IMV (PS 12-PEEP 5): PaO2 86, PaCO2 53, pH 7.39<br />

21-04. EGA <strong>in</strong> O2 (2 L/m<strong>in</strong>) ed IMV (PS 10-PEEP 5): PaO2 80, Pa CO2 40, pH 7.44


FOB for Atelectasis<br />

FOB is frequently requested and often performed for ‘Pulmonary Toilet ’ or<br />

treatment of Atelectasis <strong>in</strong> critically ill patients; however, its utility <strong>in</strong><br />

prevent<strong>in</strong>g nosocomial pneumonia is limited<br />

Therapeutic role of bronchoscopy <strong>in</strong> acute atelectasis is limited and<br />

transient, and should be reserved primarily for patients with acute<br />

atelectasis <strong>in</strong>volv<strong>in</strong>g more than a s<strong>in</strong>gle lung segment <strong>in</strong> the absence of air<br />

bronchograms who rema<strong>in</strong> symptomatic after 24 hours of chest<br />

physiotherapy<br />

Cl<strong>in</strong>ical experience <strong>in</strong><strong>di</strong>cates that atelectasis recurs frequently after FOB if<br />

the cause of compromised airway hygiene cont<strong>in</strong>ues.<br />

There is no role<br />

for empiric ‘clean<strong>in</strong>g of the airways’ with a FOB<br />

Critical Care 2008, 12:209 (doi:10.1186/cc6830)


Hemoptysis


Protezione delle vie aeree<br />

Localizzazione fonte<br />

<strong>di</strong> sangu<strong>in</strong>amento<br />

Trattamento<br />

Gestione dell’emottisi<br />

•IOT<br />

•IOT selettiva<br />

• FBS<br />

• FB rigido<br />

• Angiotc<br />

• Arteriografia<br />

La sede del sangu<strong>in</strong>amento è misconosciuta nel 60% dei casi<br />

•Temporaneo fb<br />

•Embolizzazione<br />

•chirurgia<br />

Mortalità variabile: 30-85%.<br />

85% +


Caso cl<strong>in</strong>ico: SL<br />

anni 52, sesso F<br />

non fumatrice<br />

Epilessia dall’<strong>in</strong>fanzia<br />

R<strong>in</strong>ite allergica Ipertensione Arteriosa<br />

NCH (22/07/2008): <strong>in</strong>tervento per neur<strong>in</strong>oma angolo pontocerebellare<br />

sx: nel PO IR: IOT e poi tracheo<br />

05/09/2008: trasferita <strong>in</strong> UTIP per wean<strong>in</strong>g<br />

SL 05/09/08<br />

Opacamento emitorace dx<br />

per versamento pleurico<br />

associato a verosimile<br />

addensamento<br />

parenchimale a sede<br />

sovra<strong>di</strong>aframmatica<br />

paracar<strong>di</strong>aca dx. M<strong>in</strong>imi<br />

sfumati addensamenti<br />

alveolari a sede parailare<br />

sn. Slargato il me<strong>di</strong>ast<strong>in</strong>o.


11/09/08: Episo<strong>di</strong>o <strong>di</strong> broncorragia<br />

FOB<br />

Asportazione <strong>di</strong> <strong>di</strong>versi coaguli<br />

<strong>in</strong> entrambi gli emisistemi e <strong>di</strong><br />

grosso coagulo a dx.<br />

NON EVIDENTI SEDI DI<br />

SANGUINAMENTO<br />

Post-FBS<br />

Rx 11/09


AngioTc<br />

e<br />

Tc Torace<br />

Lo stu<strong>di</strong>o vascolare:<br />

non evidenza <strong>di</strong> alterazioni a<br />

carico delle arterie<br />

bronchiali e della pervietà<br />

del circolo polmonare.<br />

Si verificano nei gg successivi importanti<br />

broncorragie, con progressivo peggioramento delle<br />

con<strong>di</strong>zioni generali (anemizzazione,ipotensione,<br />

necessità <strong>di</strong> sedazione profonda)


Arteriografia selettiva ed embolizzazione:<br />

15/09/08 e 18/09/08<br />

I II<br />

15/09<br />

Embolizzazione <strong>di</strong> rami del Circolo bronchiale<br />

18/09


Angiografia data: 08/10<br />

Dilatazioni pseudoaneurismatiche a livello<br />

delle <strong>di</strong>ramazioni delle arterie polmonari<br />

20/10 EMOTTISI MASSIVA: exitus<br />

Diagnosi autoptica: Broncopolmonite a focolai<br />

multipli associata ad emorragia broncoalveolare<br />

sullo sfondo <strong>di</strong> vasculite granulomatosa<br />

giagantocellulare delle aa bronchiali e spleniche<br />

Tc con e senza mdc data: 11/10


Manag<strong>in</strong>g life-threaten<strong>in</strong>g hemoptysis.<br />

Haponick EF et al.<br />

Da un’<strong>in</strong>dag<strong>in</strong>e sulla gestione delle emottisi massive a Toronto svoltasi<br />

<strong>in</strong> occasione <strong>di</strong> un’assemblea dell’ACCP emerge che:<br />

• il FOB è sempre più utilizzato e preferito vs FB rigido ed <strong>in</strong> genere<br />

entro 24 h dall’esor<strong>di</strong>o (79 %),<br />

• il 95 % degli <strong>in</strong>tervistati preferiva il ricovero dei pz <strong>in</strong> ICU,<br />

• l’ 85% preferiva l’<strong>in</strong>tubazione precoce,<br />

• il 50% ricorreva all’embolizzazione arteriosa.<br />

Conclusioni gestione emottisi<br />

Chest 2000; 118: 1431-1435.<br />

La scelta degli strumenti e meto<strong>di</strong>che è sicuramente<br />

<strong>di</strong>pendente dalla tipologia organizzativo-strutturale<br />

del centro e dall’esperienza dell’operatore.


Difficult <strong>in</strong>tubation<br />

and<br />

tracheal tube position<strong>in</strong>g


Caso cl<strong>in</strong>ico IM:80 aa<br />

• BPCO <strong>in</strong> OTLT con numerose riacutizzazioni<br />

• Ipertensione Arteriosa, Diabete Mellito tipo 2<br />

• nel 2010: 3 ricoveri necessitanti IOT<br />

• nel 2011: episo<strong>di</strong>o <strong>di</strong> IRCR necessitante IRT, visita ORL pos-estubazione: proposta<br />

tracheostomia per paralisi dei postici<br />

Paziente rifiuta tracheostomia<br />

2°Ingresso UTIR<br />

Inviata <strong>in</strong> UTIR per IRCR:<br />

La pz accetta <strong>in</strong><strong>di</strong>cazione a<br />

tracheostomia!<br />

peggioramento degli scambi respiratori e del sensorio<br />

IOT <strong>di</strong>fficile Intubazione r<strong>in</strong>otracheale FBS Guidata


Airway Management<br />

In<br />

Intubated Patients


Caso cl<strong>in</strong>ico BM: 79 aa<br />

•Recente ESA e TEP. Diagnosi <strong>di</strong> SLA febbraio 2011<br />

•Ipertensione Arteriosa, Insuff.renale ed Anemia cronica<br />

• Dimessa il 13/04/11 dall’UTIR : dopo posizionamento <strong>di</strong> PEG e con <strong>in</strong><strong>di</strong>cazione a NIV<br />

notturna<br />

2°Ingresso UTIR: 29-04-<br />

2011<br />

Paziente rifiuta tracheostomia<br />

Progressivo aumento delle ore <strong>di</strong> NIV (f<strong>in</strong>o a 24h/24h)<br />

La pz accetta tracheostomia!<br />

EGA <strong>in</strong> NIV (IPAP 24-PEEP 4- FiO2 40%):<br />

PaO2 106, PaCO2 84, pH 7.34, Hb 8.3<br />

Eseguito ciclo cont<strong>in</strong>uativo notturno con<br />

NIV con maschera fullface per decubiti<br />

faciali<br />

PaO2 73, PaCO2 72, pH 7.41, Hb 7.4<br />

Emotrasfusione<br />

IOT <strong>in</strong> previsione <strong>di</strong> tracheostomia<br />

Difficile visione a<strong>di</strong>tus per paralisi corda vocale<br />

sx micosi <strong>di</strong>ffusa


30/4. EGA <strong>in</strong> IMV (ACP: P<strong>in</strong>sp 12-PEEP 5- FiO2 45%): PaO2 88, PaCO2 48, pH 7.53, Hb 9.8<br />

02/5. EGA <strong>in</strong> IMV (ACP: P<strong>in</strong>sp 12-PEEP 5- FiO2 45%): PaO2 62, PaCO2 62, pH 7.45, Hb 9.4<br />

03/5. EGA <strong>in</strong> IMV (ACP: P<strong>in</strong>sp 16-PEEP 7- FiO2 80%): PaO2 74, PaCO2 77, pH 7.36, Hb 9.0<br />

Secrezioni scarse striate ematiche, bassi Volumi correnti <strong>in</strong> IMV-ACP<br />

Rx torace: tubo normoposizionato, esame <strong>in</strong>variato verso precedente<br />

FBS<br />

grosso coagulo a cavaliere della<br />

carena tracheale che ostruisce quasi<br />

<strong>in</strong>teramente il BPdx!


Dopo <strong>di</strong>sostruzione e sollevamento del TT, evidenza <strong>di</strong> lesione della parete<br />

posteriore della trachea<br />

EGA <strong>in</strong> IMV (ACP: P<strong>in</strong>sp 14-PEEP 6- FiO2 80%): PaO2 152, PaCO2 43, pH 7.53<br />

Consulenza ORL: soprassiede sull’<strong>in</strong><strong>di</strong>cazione <strong>di</strong> tracheostomia. Richiesta Tc torace<br />

collo con mdc ed esito <strong>di</strong> biopsie sulla mucosa <strong>in</strong>teressata<br />

Anemizzazione-- emotrasfusione


Lesione tracheale a partenza dalla pars membranacea della<br />

trachea a pieno spessore che si aggetta nel lume <strong>in</strong>vadendo il BP<br />

<strong>di</strong> dx e posteriormente l’esofago<br />

Tc torace precedente (30/12/2011) evidenza <strong>di</strong> ispessimento pseudonodulare a livello<br />

del BLS dx. TEP risolta.<br />

PET (11/01/2011): negativa<br />

EGDS (8/04/2011): non evidenza <strong>di</strong> lesioni significative


FOB IN WEANING FAILURE<br />

AND BEFORE DECANNULATION<br />

Failure to extubate and the impossibility to remove<br />

the tracheostomy cannula can reflect a mechanical<br />

problem which <strong>in</strong>creases the work of breath<strong>in</strong>g.<br />

Specific problems that can be <strong>di</strong>agnosed by FOB are:<br />

1) airway granulation tissue result<strong>in</strong>g <strong>in</strong><br />

airway obstruction,<br />

2) tracheal stenosis post-<strong>in</strong>tubation,<br />

3) tracheal bronchial malacia


Glottide:<br />

normale visione<br />

STENOSI SOTTOGLOTTICA<br />

Post-<strong>in</strong>tubazione<br />

La FOB consente <strong>di</strong> poter <strong>di</strong>agnosticare stenosi<br />

tracheali precocemente e <strong>in</strong><strong>di</strong>rizzare il paziente a<br />

trattamenti terapeutici specifici (<strong>di</strong>latazioni<br />

endoscopiche, laser, stent, chirurgia) spesso risolutivi.


Conventional bronchoscopic images on <strong>in</strong>spiration (C) and expiration (D) confirm non<br />

contrast CT f<strong>in</strong><strong>di</strong>ngs.


CONCLUSION<br />

FOB is a very versatile technique <strong>in</strong> the contex<br />

of <strong>in</strong>tensive care.<br />

Safety is of paramount importance <strong>in</strong> critically<br />

<strong>in</strong>stable patients.<br />

A skilled team with specific expertice and<br />

appropriate sett<strong>in</strong>g are required.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!